Using the EAVE II cohort to investigate the effectiveness of currently administered or future approved vaccines by dose, viral variants and patient clinical and demographic characteristics. HTML Summary (research in a nutshell) As the vaccine programme in the UK continues, currently with the third and ‘booster’ programme, it is important to study post-vaccine breakthrough with SARS-CoV-2 infection. Understanding who remains at risk after receiving booster vaccination can help identify who is most likely to benefit from additional vaccine regimens or other interventions (e.g. shielding or monoclonal antibodies) to reduce risk. Our aim is to investigate booster vaccine dose breakthroughs in the context of the rapidly changing epidemiological picture of SARS-CoV-2 infection and emerging viral variants. We will initially conduct a national prospective population-based cohort using EAVE II data (which includes vaccination status, primary care, secondary care, laboratory test, anti-SARS-CoV-2 IgG antibodies, viral variants and genomics, and mortality across Scotland). This will be used to assess the effectiveness of currently administered vaccines, and any future approved vaccines, by vaccine dose, viral variants, and patient clinical and demographic characteristics. We will then use national data from other UK nations to undertake an independent external replication of our findings. Key People Aziz Sheikh Principal Investigator Chris Robertson Lead for Scotland Simon de Lusignan Lead for England Declan Bradley Lead for Northern Ireland Ronan Lyons Lead for Wales Samantha Lycett Co-lead for Scotland Vahe Nafilyan Co-lead for England (ONS) Lynsey Patterson Co-lead for Northern Ireland Ashley Akbari Co-lead for Wales Ahmar Shah Lead analyst Mark Joy Lead analyst Colin McCowan Lead analyst Steven Kerr Lead analyst Natalia Reglinska-Matveyev Project Manager (University of Edinburgh) Sneha Anand Project Manager (University of Oxford) Lana Woolford Patient Public Involvement Lead Contact Natalia Reglinska-Matveyev Natalia.Matveyev@ed.ac.uk Key Collaborators BREATHE DaC-VaP EAVE II Scotland Public Health Scotland University of St. Andrews University of Strathclyde England University of Oxford Office for National Statistics Northern Ireland Queens University Belfast Public Health Agency Wales Swansea University Public Health Wales Website Vaccine Breakthrough is a incorporated project of EAVE II. Visit the EAVE II website for more information. EAVE II Connected Projects Webpage Funders and Partners UK Research and Innovation (Medical Research Council) Scottish Government Health Data Research UK Chief Scientist Office National Institute for Health Research National Core Studies Programme: Immunity Timeline Start date: 1 January 2022 End date: 30 September 2022 This article was published on 2024-09-24
HTML Summary (research in a nutshell) As the vaccine programme in the UK continues, currently with the third and ‘booster’ programme, it is important to study post-vaccine breakthrough with SARS-CoV-2 infection. Understanding who remains at risk after receiving booster vaccination can help identify who is most likely to benefit from additional vaccine regimens or other interventions (e.g. shielding or monoclonal antibodies) to reduce risk. Our aim is to investigate booster vaccine dose breakthroughs in the context of the rapidly changing epidemiological picture of SARS-CoV-2 infection and emerging viral variants. We will initially conduct a national prospective population-based cohort using EAVE II data (which includes vaccination status, primary care, secondary care, laboratory test, anti-SARS-CoV-2 IgG antibodies, viral variants and genomics, and mortality across Scotland). This will be used to assess the effectiveness of currently administered vaccines, and any future approved vaccines, by vaccine dose, viral variants, and patient clinical and demographic characteristics. We will then use national data from other UK nations to undertake an independent external replication of our findings. Key People Aziz Sheikh Principal Investigator Chris Robertson Lead for Scotland Simon de Lusignan Lead for England Declan Bradley Lead for Northern Ireland Ronan Lyons Lead for Wales Samantha Lycett Co-lead for Scotland Vahe Nafilyan Co-lead for England (ONS) Lynsey Patterson Co-lead for Northern Ireland Ashley Akbari Co-lead for Wales Ahmar Shah Lead analyst Mark Joy Lead analyst Colin McCowan Lead analyst Steven Kerr Lead analyst Natalia Reglinska-Matveyev Project Manager (University of Edinburgh) Sneha Anand Project Manager (University of Oxford) Lana Woolford Patient Public Involvement Lead Contact Natalia Reglinska-Matveyev Natalia.Matveyev@ed.ac.uk Key Collaborators BREATHE DaC-VaP EAVE II Scotland Public Health Scotland University of St. Andrews University of Strathclyde England University of Oxford Office for National Statistics Northern Ireland Queens University Belfast Public Health Agency Wales Swansea University Public Health Wales Website Vaccine Breakthrough is a incorporated project of EAVE II. Visit the EAVE II website for more information. EAVE II Connected Projects Webpage Funders and Partners UK Research and Innovation (Medical Research Council) Scottish Government Health Data Research UK Chief Scientist Office National Institute for Health Research National Core Studies Programme: Immunity Timeline Start date: 1 January 2022 End date: 30 September 2022
